IBD Medication Guide



Brand Name(s)

Renflexis® (This drug is a biosimilar to Remicade®)

Drug Class


How taken

Intravenous (IV) infusion

Used for

Moderate-to-severe Crohn’s disease and ulcerative colitis in adults and pediatric patients

Recommendations for Pregnancy

low risk

Recommendations for Lactation

Limited human data: probably compatible

Medication indication

Infliximab-abda is indicated for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use, in adult and pediatric patients over the age of 6 with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy. Infliximab-abda is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulae and maintaining the fistulizing closure in patients with Crohn’s disease.

Indicated for pediatric use

Yes (Crohn's disease and ulcerative colitis)

Most common side effects

Infusion reactions such as hives, redness, chest pressure, itching and swelling of the lips and throat and shortness of breath, respiratory infections, such as sinus infections and sore throat; headache; coughing; stomach pain; nausea; and back pain.


There have been reports of serious infections associated with infliximab products, including tuberculosis (TB) and other infections such as viruses, fungi, and other bacteria that have spread throughout the body. On rare occasions certain types of cancer, including lymphoma, have been reported.

Learn more about biologics

Scroll right by clicking & dragging with your cursor or swiping with your finger.